Lilly Q3 2022: revenue up 2% to $6.94B, reported EPS $1.61 (+32%), Mounjaro launch strong

ELI LILLY & Co

2022-Q3 EPS reported $4.76 revenue$21,239,600,000

Revenue $6,941.6M (+2% reported, +7% constant currency); total volume +14%.
Reported EPS $1.61 (+32%); non-GAAP EPS $1.98 (+12%); both inclusive of $0.06 acquired IPR&D charges.
Mounjaro U.S. revenue $97.3M in first full quarter; plus $86.0M from Japan collaboration agreement.
Key growth products (Verzenio, Trulicity, Mounjaro, etc.) grew 19% and represented 70% of revenue (ex-COVID antibodies).
2022 EPS guidance updated: reported $6.50-$6.65, non-GAAP $7.70-$7.85, inclusive of $0.67 charges.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELI LILLY & Co reported the third quarter of 2022 results: revenue $6,941.6, net income 1,451.7, EPS $1.61.

Period: the third quarter of 2022
Revenue: $6,941.6
Net income: 1,451.7
EPS: $1.61
Result: reported results

Exact text from the filing

other important public announcements, visit the news section of Lilly's website. Financial Results $ in millions, except per share data Third Quarter % 2022 2021 Change Revenue $6,941.6 $6,772.8 2% Net Income – Reported 1,451.7 1,110.1 31% EPS – Reported 1.61 1.22 32% Net Income – Non-GAAP 1,789.2 1,614.2 11% EPS – Non-GAAP 1.98 1.77 12% A discussion of the

View on SEC.gov

Browse all earnings releases →

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-22-000248

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.